A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2002
12/03/2002	US6489446 Self-aligning peptides modeled on human elastin and other fibrous proteins
12/03/2002	US6489443 Carrying out heat treatment in glass vessel which has been rinsed out beforehand with detergent solution and then with distilled water or another detergent-free solvent
12/03/2002	US6489440 Aerothricins for the preparation of medicaments with antifunal properties
12/03/2002	US6489353 Antiinflammatory agents; autoimmune diseases; central nervous system disorders
12/03/2002	US6489330 Or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of such as famciclovir; prophylactic treatment for kaposi's sarcoma or aids related disease
12/03/2002	US6489308 One agent exhibiting mammalian alpha 1-antitrypsin or alpha 1-antitrypsin-like activity, and a free radical scavenger such as 2,6,8-trihydroxypurine, dihydrorhodamine, or a combination thereof
12/03/2002	US6489307 Reducing the level of transcription of beta 1-adrenoceptor polypeptide-specific mrna in a mammalian host cell, by administering oligonucleotide; reduces receptor expression; hypotensive effect
12/03/2002	US6489306 Method of intranasal gene transfer for protection against respiratory infection
12/03/2002	US6489300 Inhibitors of adhesion in the treatment of inflammatory brain diseases and other inflammatory conditions
12/03/2002	US6489299 Lysine at position 91 is altered to another amino acid.
12/03/2002	US6489298 Contulakin-G, analogs thereof and uses thereof
12/03/2002	US6489297 Anti-neoplastic activity of novel vip peptide analogs using selected constrained amino acids such as diethylglycine, 1-aminocyclopentane carboxylic acid and di-n-propylglycine
12/03/2002	US6489296 Treatment of hypercoagulable states or acquired protein c deficiency with activated protein c, a highly selective therapeutic agent with a low potential for causing bleeding complications
12/03/2002	US6489295 Antagonists of intestinotrophic GLP-2 peptides
12/03/2002	US6489294 Truncated insulin-like growth factor binding protein-5 having mitogenic activity
12/03/2002	US6489293 Recombinant human erythropoietin with altered biological activity
12/03/2002	US6489292 Stable aqueous insulin preparations without phenol and cresol
12/03/2002	US6489291 Topical composition for skin
12/03/2002	US6489290 Antiplatelet agent
12/03/2002	US6489289 Method for establishing a dosage plan for thrombin inhibitors
12/03/2002	US6489288 Treatment of polycystic ovarian disease
12/03/2002	US6489163 Method for inhibiting the proliferation of prostatic cancer cells in vitro, comprising providing to said cells a vector that expresses a synthetic ribozyme
12/03/2002	US6489153 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
12/03/2002	US6489144 Culturing cells that overproduce double-stranded-rna-dependent kinase and treatment with inducer
12/03/2002	US6489143 Mutant plasminogen activator-inhibitor type 1 (PAI-1) proteins
12/03/2002	US6489139 FabZ from Staphylococcus aureus
12/03/2002	US6489138 Diagnosing nervous system disorders; gene expression and engineering
12/03/2002	US6489136 Cell proliferation related genes
12/03/2002	US6489128 Methods for detecting cancer of the central nervous system
12/03/2002	US6489123 Labelling and selection of molecules
12/03/2002	US6489122 Chlamydia pneumoniae antigenic polypeptides, which comprise polypeptide a containing a sequence of at least 5 consecutive amino acids in the polypeptide of seq id no: 1, dnas encoding the antigenic polypeptides, or dnas complementary thereto;
12/03/2002	US6489118 Nucleotide sequences coding preferential peptides; for use in diagnosing and treatment of allergies
12/03/2002	US6489101 Breast tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a breast tumor protein, or a t cell that
12/03/2002	US6488933 Preparations for the treatment of T cell mediated diseases
12/03/2002	US6488932 Method for treating cancer by administering MAGE-derived peptides
12/03/2002	US6488931 Immunotherapy
12/03/2002	US6488928 Product for topical application containing a lipase and a hydroxy acid precursor
12/03/2002	US6488927 Fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.
12/03/2002	US6488925 Macrophage inflammatory protein-4 (MIP-4) polypeptides
12/03/2002	CA2414000A1 Pyridin-2-ylaminoalkylcarbonylglycyl-beta-alanine and derivatives
12/03/2002	CA2284077C Variants of ciliary neurotrophic factor with enhanced receptor selectivity and method for their selection
12/03/2002	CA2213198C Gene therapy by anti-tgf-b agents
12/03/2002	CA2126103C Transfection of lung via aerosolized transgene delivery
12/03/2002	CA2116478C Prolonged delivery of peptides
12/03/2002	CA2116120C Peptides having growth hormone releasing activity
12/03/2002	CA2107481C Osteoinductive protein mixtures and purification processes
12/03/2002	CA2092914C Synergism of tnf and il-4
12/03/2002	CA2073856C Glp-1 analogs useful for diabetes treatment
12/03/2002	CA2060544C Recombinant antibodies specific for a growth factor receptor
12/03/2002	CA2050910C Human intra-acrosomal sperm antigen for use in a contraceptive vaccine
12/03/2002	CA1341406C Crf analogs
11/2002
11/29/2002	CA2389552A1 Composition for the treatment of cutaneous signs of aging
11/28/2002	WO2002095067A2 INTERFERON α-14 POLYMORPHISM
11/28/2002	WO2002095062A2 Serine-threonine phosphatase protein of a parasitic organism of the apicomplexa phylum, applications in therapeutics
11/28/2002	WO2002095053A2 Antisense modulation of src-c expression
11/28/2002	WO2002095051A2 Mage-a3 peptides presented by hla class ii molecules
11/28/2002	WO2002095049A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
11/28/2002	WO2002095041A1 Virus high effectively expressing the tumor interferon and specifically reproduction in tumor cells and the use thereof
11/28/2002	WO2002095038A2 Vectors for enhanced expression of vegf for disease treatment
11/28/2002	WO2002095034A2 A retinoic acid metabolizing cytochrome p450
11/28/2002	WO2002095032A2 Methods and compositions of human proteins and uses thereof.
11/28/2002	WO2002095030A2 Modulation of cd200 receptors
11/28/2002	WO2002095029A2 Nucleic acid and protein sequences of bovine epidermal growth factor
11/28/2002	WO2002095026A1 Method of proliferating terminal differentiated cells and recombinant vector therefor
11/28/2002	WO2002095018A1 Regulation of human zinc carboxypeptidase b-like protein
11/28/2002	WO2002095017A1 Novel mixed lineage kinase (7) (mlk7) polypeptide, polynucleotides encoding the same, and methods of use thereof
11/28/2002	WO2002095016A2 Champ - a cardiac helicase-like factor
11/28/2002	WO2002095015A1 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody
11/28/2002	WO2002095011A2 Inactivation of genes of the mep pathway
11/28/2002	WO2002095010A2 Human secreted proteins
11/28/2002	WO2002095009A2 Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer
11/28/2002	WO2002095008A2 Methods of modulating surfactant phospholipid production
11/28/2002	WO2002095007A2 Conjugates activated by cell surface proteases and therapeutic uses thereof
11/28/2002	WO2002095006A2 Muscle-specific expression vectors
11/28/2002	WO2002095003A2 Phytases, nucleic acids encoding them and methods for making and using them
11/28/2002	WO2002095001A2 Btf3: an inhibitor of apoptosis
11/28/2002	WO2002094997A2 Transcriptional regulation of target genes
11/28/2002	WO2002094988A2 Lipid-associated molecules
11/28/2002	WO2002094985A2 Beta-secretase substrates and uses thereof
11/28/2002	WO2002094980A2 Phytocystatin
11/28/2002	WO2002094875A1 HAb18G/CD147, IT'S AGONIST AND APPLICATION
11/28/2002	WO2002094874A2 Internalisation of virus into cells
11/28/2002	WO2002094873A2 Preparation of cholecystokinin agonists and antagonists, and their therapeutic and diagnostic use
11/28/2002	WO2002094872A1 Therapeutic uses of keratinocyte growth factor-2
11/28/2002	WO2002094871A1 Novel keratinocyte growth factor-2 analogue in hair follicle
11/28/2002	WO2002094870A2 Proteins and nucleic acids encoding same
11/28/2002	WO2002094869A1 Lectin protein prepared from maackia fauriei, process for preparing the same and the use thereof
11/28/2002	WO2002094868A2 Staphylococcus aureus proteins and nucleic acids
11/28/2002	WO2002094864A2 Human cdnas and proteins and uses thereof
11/28/2002	WO2002094863A2 INTERFERON-α INDUCED GENE
11/28/2002	WO2002094862A2 Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
11/28/2002	WO2002094860A2 Dimerized t-cell receptor fragment, its compositions and use
11/28/2002	WO2002094858A1 Antiviral compounds derived from the non-glycosylated central subdomain of respiratory syncytial virus (rsv) protein g.
11/28/2002	WO2002094856A2 Gpe analogs and peptidomimetics
11/28/2002	WO2002094852A2 Taci-immunoglobulin fusion proteins
11/28/2002	WO2002094848A1 Treatment of mycobacterium tuberculosis with antisense oligonucleotides
11/28/2002	WO2002094780A2 Kinases and phosphatases
11/28/2002	WO2002094775A2 Recombinant simian gpr3 receptor
11/28/2002	WO2002094407A2 Protein fractionation and single p0lymer matrix unit chromatography
11/28/2002	WO2002094378A2 Increased functional activity and/or expression of abc transporters protects against the loss of dopamine neurons associated with parkinson's disease

1 ... 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 ... 3163